171 related articles for article (PubMed ID: 32640211)
1. The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.
Almutairi M; Gopal K; Greenwell AA; Young A; Gill R; Aburasayn H; Al Batran R; Chahade JJ; Gandhi M; Eaton F; Mailloux RJ; Ussher JR
Can J Cardiol; 2021 Jan; 37(1):140-150. PubMed ID: 32640211
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
3. FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity.
Gopal K; Al Batran R; Altamimi TR; Greenwell AA; Saed CT; Tabatabaei Dakhili SA; Dimaano MTE; Zhang Y; Eaton F; Sutendra G; Ussher JR
Cell Rep; 2021 Apr; 35(1):108935. PubMed ID: 33826891
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH dependent manner.
Chan JSF; Greenwell AA; Saed CT; Stenlund MJ; Mangra-Bala IA; Tabatabaei Dakhilli SA; Yang K; Ferrari SR; Eaton F; Gopal K; Ussher JR
J Endocrinol; 2024 Jun; ():. PubMed ID: 38860519
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats.
Inoue T; Inoguchi T; Sonoda N; Hendarto H; Makimura H; Sasaki S; Yokomizo H; Fujimura Y; Miura D; Takayanagi R
Atherosclerosis; 2015 May; 240(1):250-9. PubMed ID: 25818251
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes.
Monji A; Mitsui T; Bando YK; Aoyama M; Shigeta T; Murohara T
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(3):H295-304. PubMed ID: 23709595
[TBL] [Abstract][Full Text] [Related]
8. Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction.
Karwi QG; Zhang L; Wagg CS; Wang W; Ghandi M; Thai D; Yan H; Ussher JR; Oudit GY; Lopaschuk GD
Cardiovasc Diabetol; 2019 Jan; 18(1):1. PubMed ID: 30626440
[TBL] [Abstract][Full Text] [Related]
9. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
Moffett RC; Patterson S; Irwin N; Flatt PR
Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide Effect on Ventricular Transient Outward K + Channel and Connexin-43 Protein Expression.
Ramadan NM; Malek HA; Rahman KA; El-Kholy E; Shaalan D; Elkashef W
Exp Clin Endocrinol Diabetes; 2021 Dec; 129(12):899-907. PubMed ID: 32559789
[TBL] [Abstract][Full Text] [Related]
11. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
Withaar C; Meems LMG; Markousis-Mavrogenis G; Boogerd CJ; Silljé HHW; Schouten EM; Dokter MM; Voors AA; Westenbrink BD; Lam CSP; de Boer RA
Cardiovasc Res; 2021 Jul; 117(9):2108-2124. PubMed ID: 32871009
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways.
Zhou JY; Poudel A; Welchko R; Mekala N; Chandramani-Shivalingappa P; Rosca MG; Li L
Eur J Pharmacol; 2019 Oct; 861():172594. PubMed ID: 31412267
[TBL] [Abstract][Full Text] [Related]
13. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation.
Gopal K; Karwi QG; Tabatabaei Dakhili SA; Wagg CS; Zhang L; Sun Q; Saed CT; Panidarapu S; Perfetti R; Ramasamy R; Ussher JR; Lopaschuk GD
Cardiovasc Diabetol; 2023 Mar; 22(1):73. PubMed ID: 36978133
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
15. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
16. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function.
Basu R; Oudit GY; Wang X; Zhang L; Ussher JR; Lopaschuk GD; Kassiri Z
Am J Physiol Heart Circ Physiol; 2009 Dec; 297(6):H2096-108. PubMed ID: 19801494
[TBL] [Abstract][Full Text] [Related]
17. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
[TBL] [Abstract][Full Text] [Related]
18. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model.
Wang Z; Wang M; Hu X; Li Y; Ma D; Li S; Zhao G; Xie Y; Shu Y; Yang J
Transplantation; 2019 Mar; 103(3):502-511. PubMed ID: 30211824
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.
Roumane A; Mcilroy GD; Sommer N; Han W; Heisler LK; Rochford JJ
Front Endocrinol (Lausanne); 2024; 15():1379228. PubMed ID: 38745956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
